The Evolving Landscape of Reduced-Intensity Conditioning: Balancing Efficacy and Toxicity Across Hematologic Malignancies.
- 1Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Orange, CA, 92868, USA. [email protected].
- 2Division of Hematology, Department of Medicine, Faculty of Medicine Naresuan Hospital, Naresuan University, Phitsanulok, Thailand. [email protected].
- 3Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Orange, CA, 92868, USA.
Abstract
Purpose
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has evolved from traditional myeloablative conditioning toward reduced-intensity conditioning (RIC) and strategies using donor-derived immune effector cells. This review summarizes trends in RIC, proposes a practical classification of regimens, and underscores personalized risk stratification and disease-specific conditioning.Recent findings
Fludarabine-based backbones combined with alkylating agents-melphalan (Flu-Mel), busulfan (Flu-Bu), or cyclophosphamide (Flu-Cy)-remain widely adopted due to favorable tolerability and antitumor activity. Large CIBMTR analyses indicate melphalan-based RIC confers superior long-term survival in older patients with myeloid malignancies, primarily through reduced relapse rates. The emergence of integrated prognostic tools such as the Hematopoietic Cell Transplant-Composite Risk (HCT-CR) score and the HCT Frailty Scale enhances pretransplant risk assessment and patient selection. Incorporation of measurable residual disease (MRD) testing and next-generation sequencing (NGS) chimerism refines conditioning intensity decisions and enables earlier relapse detection and intervention. While most prospective trials have focused on AML and MDS, accumulating evidence supports RIC efficacy in selected patients with ALL and various lymphomas. Collectively, data emphasize that optimal conditioning is disease-, risk-, and patient-specific, requiring tailored approaches. RIC has extended allo-HSCT to older, frailer patients, achieving outcomes comparable to myeloablative regimens despite relapse risk. Future work should prioritize prospective disease-specific trials comparing RIC regimens; integration of dynamic biomarkers (MRD, immune profiling, NGS chimerism) into adaptive conditioning; development of frailty-adjusted protocols; and evaluation of post-transplant cellular therapies and targeted maintenance to prevent relapse. These advances aim to personalize conditioning and post-transplant management to maximize survival and minimize toxicity.
Related
- Global Burden of Disease Study on the Changing Landscape of Hematologic Malignancies and the Growing Impact of Elevated Body Mass Index — Asia, 1990–2023
- Risk Factors and Outcomes of Vancomycin-Resistant Enterococcus faecium Bloodstream Infection in Hematologic Malignancies and Stem Cell Transplant Recipients: A Case-Control Study
- Non‐Relapse Mortality With Bispecific Antibodies in Hematologic Malignancies: A Dual Systematic Review and Pharmacovigilance Analysis
- Hematologic Malignancies With RUNX1::ZFPM2 Translocation: A Case Report and Literature Review
- 454 Second primary hematologic malignancies in melanoma survivors before and after the introduction of immune checkpoint inhibitors: a population-based SEER analysis
BibTeX
@article{chumnumsiriwath2026evolving,
title = {{The Evolving Landscape of Reduced-Intensity Conditioning: Balancing Efficacy and Toxicity Across Hematologic Malignancies.}},
author = {Piyatida Chumnumsiriwath and Stefan O Ciurea and Piyanuch Kongtim},
journal = {Current hematologic malignancy reports},
year = {2026},
month = oct,
doi = {10.1007/s11899-026-00791-4},
url = {https://europepmc.org/article/MED/42955162},
note = {CC BY},
}
RIS
TY - JOUR
TI - The Evolving Landscape of Reduced-Intensity Conditioning: Balancing Efficacy and Toxicity Across Hematologic Malignancies.
AU - Piyatida Chumnumsiriwath
AU - Stefan O Ciurea
AU - Piyanuch Kongtim
PY - 2026
DA - 2026/10/29
JO - Current hematologic malignancy reports
DO - 10.1007/s11899-026-00791-4
UR - https://europepmc.org/article/MED/42955162
AB - Purpose Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has evolved from traditional myeloablative conditioning toward reduced-intensity conditioning (RIC) and strategies using donor-derived immune effector cells. This review summarizes trends in RIC, proposes a practical classification of regimens, and underscores personalized risk stratification and disease-specific conditioning.Recent findings Fludarabine-based backbones combined with alkylating agents-melphalan (Flu-Mel), busulfan (Flu-Bu), or cyclophosphamide (Flu-Cy)-remain widely adopted due to favorable tolerability and antitumor activity. Large CIBMTR analyses indicate melphalan-based RIC confers superior long-term survival in older patients with myeloid malignancies, primarily through reduced relapse rates. The emergence of integrated prognostic tools such as the Hematopoietic Cell Transplant-Composite Risk (HCT-CR) score and the HCT Frailty Scale enhances pretransplant risk assessment and patient selection. Incorporation of measurable residual disease (MRD) testing and next-generation sequencing (NGS) chimerism refines conditioning intensity decisions and enables earlier relapse detection and intervention. While most prospective trials have focused on AML and MDS, accumulating evidence supports RIC efficacy in selected patients with ALL and various lymphomas. Collectively, data emphasize that optimal conditioning is disease-, risk-, and patient-specific, requiring tailored approaches. RIC has extended allo-HSCT to older, frailer patients, achieving outcomes comparable to myeloablative regimens despite relapse risk. Future work should prioritize prospective disease-specific trials comparing RIC regimens; integration of dynamic biomarkers (MRD, immune profiling, NGS chimerism) into adaptive conditioning; development of frailty-adjusted protocols; and evaluation of post-transplant cellular therapies and targeted maintenance to prevent relapse. These advances aim to personalize conditioning and post-transplant management to maximize survival and minimize toxicity.
SN - 1558-8211
SN - 1558-822X
ER -